Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Proteome analysis for downstream targets of oncogenic KRAS--the potential participation of CLIC4 in carcinogenesis in the lung.

Okudela K, Katayama A, Woo T, Mitsui H, Suzuki T, Tateishi Y, Umeda S, Tajiri M, Masuda M, Nagahara N, Kitamura H, Ohashi K.

PLoS One. 2014 Feb 4;9(2):e87193. doi: 10.1371/journal.pone.0087193. eCollection 2014.

2.

A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: potential involvement of miR-31 in lung carcinogenesis.

Okudela K, Suzuki T, Umeda S, Tateishi Y, Mitsui H, Miyagi Y, Ohashi K.

Oncol Rep. 2014 Oct;32(4):1374-84. doi: 10.3892/or.2014.3339. Epub 2014 Jul 18.

PMID:
25050641
3.

Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.

Sudhir PR, Chen CH, Pavana Kumari M, Wang MJ, Tsou CC, Sung TY, Chen JY, Chen CH.

Mol Cell Proteomics. 2012 Oct;11(10):901-15. Epub 2012 Jul 3.

4.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.

5.

Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.

Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, Mitsui H, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Takahashi T, Sugimura H, Kitamura H.

Am J Pathol. 2009 Aug;175(2):867-81. doi: 10.2353/ajpath.2009.080489. Epub 2009 Jul 16.

6.

Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, Brambilla E, Hainaut P, Soria JC.

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.

PMID:
24169260
7.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

8.

Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.

Woo T, Okudela K, Mitsui H, Tajiri M, Rino Y, Ohashi K, Masuda M.

PLoS One. 2015 Nov 6;10(11):e0142642. doi: 10.1371/journal.pone.0142642. eCollection 2015.

9.

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A.

Int J Cancer. 2014 Oct 15;135(8):1812-21. doi: 10.1002/ijc.28828. Epub 2014 Mar 14.

10.

Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers.

Suh KS, Crutchley JM, Koochek A, Ryscavage A, Bhat K, Tanaka T, Oshima A, Fitzgerald P, Yuspa SH.

Clin Cancer Res. 2007 Jan 1;13(1):121-31.

11.

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.

Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F.

Am J Clin Oncol. 2014 Aug;37(4):343-9. doi: 10.1097/COC.0b013e31827a7e7a.

PMID:
23357969
12.

Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.

McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, Solon M, Tao J, Li L, Shames D, Jackson E, Forrest WF, Firestein R.

Clin Cancer Res. 2013 Feb 15;19(4):773-84. doi: 10.1158/1078-0432.CCR-12-2638. Epub 2012 Dec 6.

13.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

14.

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA.

J Clin Invest. 2010 Nov;120(11):3940-52. doi: 10.1172/JCI44165. Epub 2010 Oct 25.

15.

Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.

Okudela K, Mitsui H, Suzuki T, Woo T, Tateishi Y, Umeda S, Saito Y, Tajiri M, Masuda M, Ohashi K.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):213-20. eCollection 2014.

16.

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP.

J Thorac Oncol. 2010 Feb;5(2):169-78. doi: 10.1097/JTO.0b013e3181c8cbd9.

17.

Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.

Ayyoub M, Memeo L, Alvarez-Fernández E, Colarossi C, Costanzo R, Aiello E, Martinetti D, Valmori D.

Cancer Immunol Res. 2014 Oct;2(10):943-8. doi: 10.1158/2326-6066.CIR-13-0211. Epub 2014 May 27.

18.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

19.

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.

20.

Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: its implication in carcinogenesis.

Okudela K, Woo T, Yazawa T, Ogawa N, Tajiri M, Masuda M, Kitamura H.

Lung Cancer. 2009 Dec;66(3):287-91. doi: 10.1016/j.lungcan.2009.02.025. Epub 2009 Apr 11.

PMID:
19362747

Supplemental Content

Support Center